March 25 (Reuters) – U.S. Food and Drug Administration staff members said on Friday Acadia Pharmaceuticals Inc’s drug to treat psychosis associated with Parkinson’s disease was effective enough to…
The post FDA staff backs Acadia’s drug to treat psychosis associated with Parkinson’s disease appeared first on NASDAQ.